A recent study shows that for patients with hypertrophic cardiomyopathy, myocardial late gadolinium enhancement on contrast-enhanced MRI may be a risk factor for cardiac death, preliminary research suggests.

The study of 424 patients with hypertrophic cardiomyopathy who underwent contrast-enhanced 1.5-tesla MRI (Signa CV/i, GE Healthcare, Chalfont St. Giles, U.K.) over a six-year period showed that late gadolinium enhancement (LGE) involving 5% or more of left ventricular mass was an independent predictor of cardiac death or appropriate implantable cardioverter defibrillator (ICD) discharges.

"Myocardial late gadolinium enhancement on contrast-enhanced images may be a sign of intramyocardial fibrosis," Dr. Ronen Rubinshtein, a fellow in cardiovascular disease at the Mayo Clinic in Rochester, MN, told Aunt Minnie.com. "We explored whether the presence and extent of LGE on MRI among these patients can predict ventricular arrhythmogenicity and decreased cardiac survival."
Rubinshtein presented these results at the American Heart Association (AHA) conference in New Orleans in November.

Of the 424 patients, 239 (56%) had late gadolinium enhancement ranging from 0.4% to 65% of the myocardium. "The most common location for late gadolinium enhancement--in 73% of cases-was the right ventricular insertion points," he said.

In 220 patients who underwent Holter electrocardiogram (ECG) during the same time period as MRI, the researchers compared the presence and amount of late gadolinium enhancement with the degree of ventricular ectopy. Results showed that patients with positive LGE were more likely to have nonsustained ventricular tachycardia: 34 of 126 patients (27%), versus eight of 94 (8.5%) without positive LGE.

"They were also more likely to have a high number of ventricular beats: 700 ventricular extrasystoles in 24 hours, versus 460 in the nonpositive group," Rubinshtein said.

During a mean follow-up period of three years, five patients died from cardiac causes and four of 41 patients with ICDs received appropriate discharges. All nine patients had late gadolinium enhancement, and six of the nine had LGE that involved 5% or more of the left ventricular mass.

"These findings are very preliminary. But if replicated, late gadolinium enhancement might be considered a major risk factor for cardiac death in patients with hypertrophic cardiomyopathy," Rubinshtein said.

More Industry Headlines